| answer text |
<p>We are aware of the supply issues with the three enzyme replacement therapies,
Creon 10,000 gastro-resistant capsules, Creon 25,000 gastro-resistant capsules, and
Nutrizym 22 capsules. These are due to manufacturing and active pharmaceutical ingredient
constraints. The Department will be issuing updated guidance to healthcare professionals
regarding treatment of patients while there is a disruption to the supply of these
pancreatic enzyme replacement therapies. We are having regular conversations with
the suppliers of these products to help drive the resolution of these issues as quickly
as possible, for example by expediting orders and increasing forecasts. We are also
working with specialist importers to source unlicensed imports from abroad.</p><p>Whilst
we can’t always prevent supply issues, we have a range of well-established tools and
processes to mitigate risks to patients. These include close and regular engagement
with suppliers, use of alternative strengths or forms of a medicine to allow patients
to remain on the same product, expediting regulatory procedures, sourcing unlicensed
imports from abroad, adding products to the restricted exports and hoarding list,
use of Serious Shortage Protocols, and issuing National Health Service communications
to provide management advice and information on the issue to healthcare professionals,
so they can advise and support their patients.</p>
|
|
